.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Sialylation of glycans remains a cornerstone of cellular signaling and health. Specifically, the ST3GAL sialyltransferases specificity determines how sialic acid attaches to galactose residues. Such processes are vital for skin cell function. Researchers recently used CRISPR/Cas9 technology to investigate these enzymes in N/TERT-1 keratinocytes.
The study explored how different ST3GAL enzymes influence glycan biosynthesis. For instance, removing ST3GAL1 significantly reduced sialylation on type 3 epitopes. However, the scientists only saw a complete loss of sialylation when they combined ST3GAL1 and ST3GAL2 knockouts. This suggests that these enzymes have overlapping roles in the skin.
Furthermore, ST3GAL4 and ST3GAL6 appear to target type 1 and type 2 epitopes. While ST3GAL4 has a major impact, ST3GAL6 functions mostly in tandem with it. Interestingly, ST3GAL5 remains the primary regulator for lactosylceramide sialylation. In contrast, ST3GAL3 does not show a clear preference between different substrates. Consequently, enzyme competition and substrate availability shape the final glycosylation landscape. These findings help explain how dysregulation leads to diseases like squamous cell carcinoma.
ST3GAL enzymes regulate the sialylation of proteins and lipids in keratinocytes. Abnormal expression of these enzymes often correlates with skin cancer progression and inflammatory disorders. Understanding their specificities helps identify potential therapeutic targets.
ST3GAL1 primarily targets type 3 epitopes on O-glycans. While ST3GAL2 has a more limited effect on its own, it works together with ST3GAL1 to ensure complete sialylation of core 1 structures.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or a professional relationship. Refer to the latest local and national guidelines for clinical practice.
References
Hipgrave Ederveen AL et al. Mapping ST3GAL Transferase Specificities in the Glycosylation Landscape of N/TERT-1 Keratinocytes Using Glycogenomics and Mass Spectrometry. Glycobiology. 2026 Jun 11. doi: undefined. PMID: 42275133.
de-Freitas-Junior JC et al. Expression patterns of α2,3-Sialyltransferase I and α2,6-Sialyltransferase I in human cutaneous epithelial lesions. PMC. 2016.
Büll C et al. Sialyltransferase Inhibitors for the Treatment of Cancer Metastasis: Current Challenges and Future Perspectives. MDPI. 2021.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
A study uses CRISPR/Cas9 to map the specificities of the ST3GAL sialyltransferase family in N/TERT-1 keratinocytes. Researchers identified how ST3GAL1-6 cooperate to regulate protein and lipid sialylation, providing key insights into the glycosylation landscape of human skin.
last month
The Central Drugs Standard Control Organisation has granted marketing authorization for Qdenga, marking India's first approved dengue vaccine. Developed by Takeda, this two-dose live-attenuated vaccine offers protection for individuals aged 4 to 60 without requiring prior serological screening.
Today
Johnson & Johnson announced a $5.5 billion settlement to resolve nearly 69,000 lawsuits alleging its talc-based baby powder caused ovarian cancer. This comprehensive deal covers 99.75% of active claims. Read about the legal strategy, scientific evidence on talc exposure, and clinical counseling for patients.
Today
Researchers at SGPGIMS Lucknow have isolated and cultured human heart valve interstitial cells from donor tissues. This milestone advances understanding of rheumatic heart disease pathways like TGF-beta/SMAD3 and ERK1/2, laying the foundation for tissue-engineered heart valves and drug testing.
Today
Anterior cruciate ligament reconstruction failure lacks uniform definition. A narrative review proposes an integrative framework incorporating objective and subjective instability, persistent pain, restricted motion, graft rupture, and secondary meniscal injury to standardize clinical reporting.
4 days back
Deepinder Goyal's healthtech startup Temple is raising capital at a $500 million valuation and pricing its temporal wearable at Rs 80,000. Worn on the side of the forehead, the device tracks microvascular blood flow and real-time Entropy to monitor physiological stress, metabolic expenditure, and recovery.
Today
